Staphylococcus epidermidis is a leading cause of foreign body-associated infections. This is related to the bacterium's ability to form biofilms on synthetic materials. Bacteria within a biofilm may be exposed to subinhibitory concentrations (sub-MICs) of antibiotics because of an agent's limited penetration into the biofilm core. Here, we investigated the effect of sub-MICs of tigecycline and ciprofloxacin on the expression of biofilm-associated genes, i.e. icaA, altE and sigB, and the biofilm structure of five clinical isolates of S. epidermidis. For most tested isolates, the expression of these genes increased after exposure to 0.25 MIC and 0.5 MIC tigecycline. A slight decrease in icaAmRNA levels was observed only in two isolates in the presence of 0.25 MIC tigecycline. The effect of ciprofloxacin exposure was isolate-dependent. At 0.5 MIC, ciprofloxacin induced an increase of sigB and icaAmRNA levels in three of the five tested isolates. At the same time, expression of the altE gene increased in all isolates (from 1.3-fold to 42-fold, depending on the strain). Confocal laser scanning microscopy analysis indicated that sub-MIC ciprofloxacin decreased biofilm formation, whereas tigecycline stimulated this process. Our data suggest that sub-MIC tigecycline may have bearing on the outcome of infections.
INTRODUCTION
Staphylococcus epidermidis is the major cause of catheterrelated bloodstream infections and other infections associated with implanted medical devices. Its pathogenesis is associated with the ability to attach to biomaterials and to develop a biofilm [1] [2] [3] [4] [5] [6] . One autolysin protein, AtlE, mediates the primary attachment of S. epidermidis cells to a polystyrene surface; it is also involved in the adhesion to vitronectin, an extracellular matrix protein which encapsulates devices after implantation into the human body [7] . The most common molecule used by S. epidermidis strains for intercellular adhesion and cell accumulation is polysaccharide intercellular adhesion (PIA), encoded by an icaADBC operon [5, 8, 9] . The expression of an ica (intercellular adhesion gene) locus is regulated by the alternative sigma factor s B , which is encoded by four genes: rsbU, rsbV, rsbW (gene encoding the s B regulator) and sigB (gene encoding s B ). The rsbU and rsbV gene products are responsible for stimulating sigB activity, whereas the rsbW gene product is a negative regulator. Synthesis of s B indirectly represses the transcription of the icaR gene, a negative regulator of icaADBC transcription, and therefore allows biofilm formation [10] .
Bacteria inside biofilms can be up to 1000 times more tolerant to antimicrobial agents than their planktonic counterparts, which may hinder eradication of biofilm-associated infections [6] . Tigecycline, a glycylcycline antibiotic, is highly active in vitro against bacteria within a biofilm [11, 12] . Tigecycline acts by inhibiting protein translation in bacteria, mediated by binding to the 30S ribosomal subunit and by blocking the association of charged tRNA to the A site of the ribosome [13] . Animal model data indicate efficient eradication of staphylococcal biofilms by tigecycline [14] . Fluoroquinolones, including ciprofloxacin, may also be useful in the treatment of biofilm-associated infections, especially when high doses of the drug are employed [15] . Ciprofloxacin acts through inhibition of DNA gyrase and topoisomerase IV activity and inhibition of DNA synthesis [16] .
It is likely that cells within a biofilm are exposed to subinhibitory concentrations (sub-MICs) of antibiotics during antibiotic chemotherapy because of the limited penetration into the biofilm core [17, 18] . Several studies have demonstrated that sub-MIC antimicrobial agents can affect the expression of S. aureus virulence determinants, such as toxins, enzymes, regulatory proteins and adhesion, and other surface proteins [17] [18] [19] [20] [21] . For example, sub-MIC tigecycline reduces the expression of tst genes that encode toxic shock syndrome toxin 1 (TSST-1) leading to reduced toxin levels in S. aureus strains [17] . Expression of the pvl gene encoding Panton-Valentine leukocidin (PVL), a pore-forming toxin that can disrupt the host cell, is also reduced in the presence of sub-MIC tigecycline [21] . Expression of other virulence-associated genes, i.e. genes encoding enzymes involved in capsule synthesis, was also reduced in the presence of a sublethal concentration of tigecycline [17] . Much less is known about the effect of sub-MIC antibiotics on the expression of virulence-associated genes and the virulence potential of S. epidermidis strains.
This study was performed to investigate the effect of sub-MIC tigecycline and ciprofloxacin on the expression of the icaA, altE and sigB genes, and on biofilm structures of clinical S. epidermidis isolates.
METHODS

Bacterial strains and antimicrobial agents
Five ica-and altE-positive biofilm-forming S. epidermidis isolates (MPU 75, MPU 51, MPU 52, MPU 57, MPU 85) were evaluated in this study. These isolates were isolated from patients with bloodstream infections and were stored as glycerol stocks at À80 C. Tigecycline (Sigma-Aldrich) and ciprofloxacin (Sigma-Aldrich) powders were as provided by the manufacturer. MIC testing was performed by broth microdilution in Mueller-Hinton II broth according to the methods of the Clinical and Laboratory Standards Institute [22] . The tigecycline MIC values were as follows: 0. 5 RNA extraction, cDNA synthesis and quantitative real-time PCR The samples were pelleted by centrifugation and the bacterial pellets were suspended in 1 ml Trizol Reagent (Sigma). Cell walls were mechanically disrupted by vigorous vortexing after mixing with glass beads (425-600 µm diameter, Sigma). Then, 100 µl 1-bromo-3-chloropropane (INC) was added. The samples were incubated with periodical mixing for 30 min at 20 C and centrifuged at 12 000 g for 15 min. The aqueous phase (450 µl) was transferred to a fresh microtube and mixed with isopropanol (500 µl) to precipitate RNA. After vigorous vortex mixing, the samples were centrifuged at 12 000 g for 10 min. The RNA pellets were washed with ice-cold 75 % ethanol to remove isopropanol and centrifuged at 12 000 g for 5 min. This step was repeated twice. Air-dried RNA samples were re-suspended in 25 µl of RNase-free water. RNA integrity was verified by analysing 5 µl of the total RNA samples by 1.5 % agarose gel electrophoresis in Tris-borate-EDTA (TBE) buffer. RNA concentration and purity were determined using the Nano-100 Micro-Spectrophotometer (Hangzhou Allsheng Instruments). cDNA was synthesized using the Thermo Scientific RevertAid First Strand cDNA Synthesis kit (Thermo Scientific) according to the manufacturer's instructions, with 1 µg of RNA as the template. Real-time amplification was performed with 500 ng cDNA, 10 µl SYBR GreenER qPCR SuperMix (Invitrogen) and 1 µl each of forward and reverse primers (200 nM each). The reaction volume was adjusted to 20 µl with RNase-and DNase-free water. Primer sequences for icaA, altE, sigB and rRNA were as published [23, 24] . Realtime PCR was performed using the CFX96 Real-Time System C1000 Touch (Bio-Rad, Hemel Hempstead, UK) and the following cycle parameters: 50 C for 2 min and 95 C for 10 min, followed by 40 cycles of 95 C for 15 s and then 60 C for 60 s. Samples for real-time RT-PCR were run in triplicate. The rRNA gene was used as an internal control to normalize the levels of expression between samples. Real-time RT-PCR data were analysed by the 2 ÀDDC t method [25] .
Confocal laser scanning microscopy (CLSM)
Bacteria were grown overnight in Mueller-Hinton II broth supplemented with the appropriate antibiotic (at 0.25 MIC and 0.5 MIC) or without antibiotics in Lab-TekII cell-culture chamber wells (Nunc) [26] . After removal of the medium and gentle washing of the wells three times with PBS to remove planktonic cells, the adherent cells were stained using SYTO stain and propidium iodide (Live/Dead BacLight Bacterial Viability kits; Invitrogen) for 15 min and observed by fluorescence microscopy (Carl Zeiss LSM 510/ Axioveut 200M). Carl Zeiss confocal software and the computer program COMSTAT were used to analyse the threedimensional biofilm images and for data analysis [27, 28] . For every sample, three microscopic fields were analysed and the means were calculated.
RESULTS AND DISCUSSION
We examined the effect of sub-MIC tigecycline and ciprofloxacin, two antibiotics used to treat staphylococcal infections, on the expression of genes encoding proteins that contribute to the pathogenicity of S. epidermidis and on the overall biofilm structure of clinical bacterial isolates.
Effect of sub-MIC tigecycline and ciprofloxacin on expression of the S. epidermidis icaA gene The icaA gene encodes a transmembrane protein with homology to N-acetyl-glucosaminyl transferases that synthesize PIA [5] . Increased icaA expression can stimulate the production of PIA, which can lead to increased intercellular adhesion of bacterial cells in a biofilm [23] . Recently, Gomes et al. [24] reported enhanced icaA expression in S. aureus strains exposed to rifampicin at sub-MIC as well as rifampicin in combination with gentamicin or clindamycin. Tetracycline, quinupristin-dalfopristin and erythromycin at sub-MICs were also found to stimulate icaA expression [23, 29] . In contrast, subinhibitory concentrations of penicillin, oxacillin, chloramphenicol, clindamycin, gentamicin, ofloxacin, vancomycin and teicoplanin had no effect on the expression of icaA [29] .
The expression of icaA was increased by onefold to 52-fold when the isolates were grown in the presence of 0.5 MIC tigecycline (Fig. 1) . Tigecycline at 0.25 MIC resulted in an increase in icaA mRNA levels (by 2.6-fold to 12.6-fold) in three of the five isolates tested, namely, MPU 52, MPU 57 and MPU 85. Under these conditions, icaA expression was slightly decreased (0.92-fold and 0.95-fold) in isolates MPU 76 and MPU 51. Tigecycline has previously been shown to reduce the expression of icaC, which encodes IcaC, the protein involved in the cytoplasmic membrane export of the extracellular poly-N-acetylglucosamine (PNAG) in S. aureus strains [17] .
As shown in Fig. 2 Effect of sub-MIC tigecycline and ciprofloxacin on expression of the S. epidermidis altE gene The altE gene encodes AtlE autolysin, which mediates the adhesion of bacteria to vitronectin and their initial attachment to polystyrene surfaces [7] . Expression of altE was increased when the S. epidermidis isolates were grown in the presence of both 0.25 and 0.5 MIC tigecycline (by 1.9-fold to 11.9-fold and by 2.2-fold to 16.1-fold, respectively). Previously, it was shown that sub-MIC tigecycline increased the expression of S. aureus genes encoding adhesion molecules, such as cna (encoding collagen-binding protein), clfB (encoding fibrinogen-binding protein) and fnbA (encoding fibronectin-binding protein) [17] . Increased expression of adhesin-encoding genes may result in more efficient microbial adhesion to biological and abiotic surfaces, which is considered the first, and probably the most crucial, step in the establishment of infection.
As shown in Fig. 2 , exposure to 0.5 MIC ciprofloxacin led to increased altE mRNA levels in all tested isolates (from 1.3-fold to 42-fold, depending on the isolates). Additionally, increased altE gene expression (by 9.9-fold to 15.6-fold) was Effect of sub-MIC tigecycline and ciprofloxacin on expression of the S. epidermidis sigB gene Tigecycline at sub-MIC concentrations led to increased sigB mRNA levels in all tested isolates. Expression of sigB was increased by >twofold in isolates MPU 76, MPU 51, MPU 52 and MPU 85 and expression of sigB increased by 1.1-fold in MPU 57 in response to 0.5 MIC tigecycline. Exposure to tigecycline at 0.25 MIC resulted in increased sigB expression in four isolates (>twofold); expression of sigB increased to a lesser extent in MPU 57 (1.3-fold). Ciprofloxacin exposure (0.5 MIC) resulted in decreased sigB expression in two isolates (MPU 76 and MPU 51). Overall, with the exception of isolates MPU 52 and MPU 57, exposure to sub-MIC tigecycline increased S. epidermidis sigB gene expression to a greater extent than sub-MIC ciprofloxacin treatment. Previous studies demonstrated the role of the sigB gene in biofilm stability [30] . However, sigB status does not affect the primary attachment of cells to plastic and the early phase of biofilm development [30, 31] . Therefore, it may be speculated that increased sigB expression may improve the structural integrity of a biofilm. Subsequently, the biofilm might become more resistant to physical forces, such as shear forces produced by blood flow. This might enable the establishment of infection and infection persistence in the host.
Effect of sub-MIC tigecycline and ciprofloxacin on the structure of S. epidermidis biofilms Following the gene expression analyses, we investigated the effect of sub-MIC tigecycline and ciprofloxacin on S. epidermidis biofilm structure in vitro. CLSM was used to visualize the biofilm structure, and the COMSTAT program was used to analyse physical biofilm parameters, i.e. biofilm thickness, the area occupied by bacterial layers, biomass (i.e. biomass volume divided by the area of view), surface area-to-biovolume ratio and roughness coefficient (an indicator of biofilm heterogeneity). The number of adherent bacteria was reduced in the presence of 0.5 MIC ciprofloxacin with changes in the overall biofilm morphology, thickness, substratum coverage and roughness (Table 1) . For example, the MPU 76 isolate exposed to ciprofloxacin formed a biofilm that was structured differently compared to that of the untreated control, i.e. the biofilm was composed of individual clusters of bacteria widely dispersed on the glass coverslip surface. The effect of ciprofloxacin was concentration-dependent, i.e. a lower number of adherent cells was observed in the presence of 0.5 MIC than in the presence of 0.25 MIC ciprofloxacin. Similarly to our results, Yassien and Khardori [15] reported that sub-MIC ciprofloxacin inhibits the adhesion of bacteria to vascular catheters, leading to reduced biofilm Table 1 . Effect of sub-MIC tigecycline (TIG) and ciprofloxacin (CIP) on the properties of biofilms formed by S. epidermidis isolates The COMSTAT program was used to analyse physical biofilm parameters, i.e. biofilm thickness, the area occupied by bacterial layers, biomass (i.e. biomass volume divided by the area of view), surface area-to-biovolume ratio and roughness coefficient (an indicator of biofilm heterogeneity. For every sample, three microscopic fields were analysed and the means were calculated. In the table we show only the P value for this test. [15] .
Exposure of S. epidermidis isolates to 0.5 MIC tigecycline resulted in a more compact three-dimensional biofilm structure, covering most of the glass coverslip surface, compared to antibiotic-untreated biofilm. We observed a change in the bacterial count and in the thickness of the biofilm formed in the presence of sub-MIC tigecycline.
This study clearly demonstrates that tigecycline and ciprofloxacin, with different antimicrobial modes of action, also affect bacteria in biofilm differently.
Our study documents the different effects of sub-MIC tigecycline and ciprofloxacin on the expression of the icaA, altE and sigB genes in clinical S. epidermidis isolates. The effect of ciprofloxacin appeared to be isolate-dependent. Generally, tigecycline treatment (both at 0.25 and 0.5 MIC) led to increased expression of the icaA, altE and sigB genes in the isolates. The only exception was isolates MPU 51 and MPU 76, where icaA mRNA levels were slightly decreased upon exposure to 0.25 MIC tigecycline. Sub-MIC tigecycline also affected biofilm architecture. These data suggest that sub-MIC tigecycline may alter the pathogenesis of staphylococcal infections. In contrast, ciprofloxacin, at levels below the MIC for bacteria, may still display anti-staphylococcal biofilm activity, thereby limiting the progression of staphylococcal disease.
Our study provides insight into the response of S. epidermidis to antimicrobial agents employed at sub-MICs or in situations where antimicrobial agents cannot achieve their MIC, e.g. when the bacteria are encased in a biofilm with decreased drug concentration in the biofilm core.
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